Algenscribe operates in the field of Gene Editing: the company is developing a new platform for Gene Replacement with its first applications in Gene Therapy and Oncology.

The aim is to achieve the full potential of Gene Editing for Gene Replacement. Algenscribe’s technologies address two major constraints of the field: the number of cells edited is significantly increased, while certain undesirable effects are reduced.

–  Therapeutic areas: Gene Editing, Gene Therapy, Oncology

–  Based in: Gif sur Yvette & Nice (FRANCE)

–  Employees: 1 – 10

–  Created in: 2022